Ligand Pharmaceuticals (LGND)
Builds biopharmaceutical royalty portfolios and licenses Captisol and NITRICIL drug technologies.
$300.79
vs last close+2.29 (+0.77%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 111.26% | 22.30M shares | |
|---|---|---|---|
| 429 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 9.60% | 1.92M shares | |
| 12 holders · as of Sep 14, 2026 | |||
| Strategic holders | 6.50% | 1.30M shares | |
| 2 holders · as of Nov 14, 2025 | |||
| Adds to | 127.36% | ||
20.04M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 127.36%; nothing is left for Other.
13F, as of Jun 30, 2026
429 holders · 22.30M shares · 99 new positions · 248 increased · 118 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.10M | 15.47% | +139.1K | Aug 7, 2026 |
| Invesco Ltd. | 1.20M | 6.00% | +378.0K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 1.14M | 5.68% | +38.0K | Aug 13, 2026 |
| Jupiter Topco LLC | 1.04M | 5.19% | +1.04Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 871.0K | 4.35% | +22.9K | Aug 13, 2026 |
| State Street Corp | 826.5K | 4.12% | +47.7K | Aug 7, 2026 |
| FMR LLC | 762.8K | 3.81% | +166.7K | Aug 13, 2026 |
| Franklin Resources Inc | 752.0K | 3.75% | +178.9K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.50% | 2.84M | 13G | Oct 17, 2025 |
| Invesco Ltd. | 6.10% | 1.22M | 13G | Aug 13, 2026 |
| Vanguard Portfolio Management | 5.56% | 1.11M | 13G | May 1, 2026 |
| Janus Henderson Group PLC | 5.30% | 1.04M | 13G | Nov 14, 2025 |
| Vanguard Capital Management | 5.00% | 997.6K | 13G | May 1, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 10, 2026 | Martine Zimmermanndirector | Sale | 1,200 | $285.00 | 3,897 |
| Sep 3, 2026 | Andrew Reardonofficer: CLO & Secretary | Sale · 5 lots | 5,000 | $286.09 | 36,514 |
| Aug 12, 2026 | Jason Haasdirector | Sale | 7,138 | $292.81 | 3,981 |
| Aug 12, 2026 | Octavio Espinozaofficer: Chief Financial Officer | Sale | 31,641 | $292.07 | 27,696 |
| Aug 3, 2026 | Andrew Reardonofficer: CLO & Secretary | Sale · 10 lots | 5,000 | $288.99 | 41,514 |
| Jul 1, 2026 | Andrew Reardonofficer: CLO & Secretary | Sale · 8 lots | 5,000 | $313.28 | 41,514 |
| Jun 16, 2026 | Stephen L. Sabbadirector | Sale | 2,145 | $254.00 | 33,629 |
| Jun 12, 2026 | Jason Haasdirector | Sale · 2 lots | 6,461 | $255.58 | 4,981 |
| Jun 10, 2026 | John L. Lamattinadirector | Sale · 4 lots | 4,591 | $250.88 | 26,969 |
| Jun 11, 2026 | Jason Aryehdirector | Sale | 4,500 | $250.00 | 102,580 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | May 29, 2026 | Jun 9, 2026 |